Germany issues award to IAVI to support development of the MTBVAC TB vaccine candidate

IAVI has announced a new award from the German government to help support the late-stage development of the promising TB vaccine candidate, MTBVAC. The German Federal Ministry of Education and Research (BMBF) through the KfW Development Bank is committed to contribute €9.2 million over the next five years to support the innovative public-private collaboration between IAVI and partners: the Spanish-based biopharmaceutical company Biofabri, a subsidiary of ZENDAL, and the Netherlands-based Tuberculosis Vaccine Initiative (TBVI). If shown to be safe and effective, IAVI and Biofabri will ensure MTBVAC is manufactured and supplied in sufficient quantities and is accessible at affordable prices in low- and middle-income countries (LMICs). This announcement follows the recent signing of an expanded agreement for end-to-end development of MTBVAC with Biofabri.